Project Grant R44GM146330
- The National Cancer Institute (NCI) awarded Pacific Northwest National Laboratory (PNNL), a division of Battelle Memorial Institute, a $450,904 Project Grant under the Cancer Biology Research program (CFDA 93.396) to develop an innovative single-cell (phospho-)proteomics platform for analyzing the tumor microenvironment (TME). The three-year award, active from September 1, 2025 through August 31, 2028, funds the development of technology to address critical limitations in current single-cell...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports research to visualize the mechanisms at the intersection of chromatin, transcription, and epigenetics. The $1,525,500 award to Harvard Medical School aims to develop a combinatorial biochemical and structural approach called "Visual Biochemistry" that uses a fully reconstituted chromatin transcription system and time-resolved single-particle...
- This $1,737,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of innovative single-cell genomics technologies for joint analysis of regulatory dynamics and transcriptional states. Key objectives include: Developing multiomics tools to measure rates of epigenomic changes (DNA methylation, demethylation, oxidative damage, DNA repair) and relate these to...
- This federal Project Grant award for $378,123 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to identify and test mechanisms that establish transcriptional regulatory potency in early embryos. The primary activities include using genomic methods like PRO-seq, DREG, and OMNI-ATAC to characterize transcriptionally active regulatory elements, DNA accessibility, and...
- Federal Project Grant Award Summary Active Motif, Inc. received a $306,094 Project Grant from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), awarded on September 20, 2025, with completion scheduled for August 31, 2026. The grant supports the development of a novel epigenetic editing platform that addresses significant limitations in current gene editing technologies. Rather than employing permanent DNA sequence alterations...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $315,060 Project Grant from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded June 10, 2025, with completion targeted for May 31, 2026. The grant supports the development of a cell-type-specific atlas of transcription factor (TF)-element connectivity across human tissues by integrating single-cell and single-nucleus Assay for...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500.00 to Yale University to conduct research on the regulatory mechanisms by which the genome encodes non-genetic heterogeneity in cell systems. The project aims to identify transcription factor pairs that drive transcriptional heterogeneity, determine heritable memory loci capable of transmitting non-genetic heterogeneity across...
- Federal Project Grant Award Summary Boston Children's Hospital received a $130,680 Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective July 1, 2025 through June 30, 2027. The award supports the development of computational technologies and statistical methods for single-cell functional genomics analysis. The research deliverables include: (1) deep learning computational frameworks to decode epigenetic...
- This $536,250 Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports computational method development to advance single-cell transcriptomic data analysis. Awarded to Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, the project runs from July 1, 2025 through June 30, 2027 and develops knowledge-guided algorithms designed to improve the detection and...
- This Project Grant award of $432,834 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) with a performance period from April 15, 2025 to March 31, 2028. The objective is to develop an enzyme-free, label-free quantitative microarray technology to accurately measure and quantify small nucleic acid targets such as microRNA in the attomolar range for applications like liquid biopsy. The research...
HIGH-THROUGHPUT SINGLE CELL CO-ASSAY OF HISTONE MODIFICATIONS ANDTRANSCRIPTOME - SUMMARY DISRUPTION OF GENE REGULATION IS A MAJOR CAUSAL FACTOR IN HERITABLE DISEASE, DEVELOPMENTAL DISORDERS, AND ONCOGENESIS. WHILE CHROMATIN IMMUNOPRECIPITATION FOLLOWED BY SEQUENCING (CHIP-SEQ) AND TN5- TRANSPOSASE BASED TAGGING (CUT & TAG) ENABLE ANALYSIS OF TRANSCRIPTION FACTOR BINDING AND EPIGENETIC STATE PROFILING IN BULK TISSUE SAMPLES AND TUMOR BIOPSIES, THEY PRODUCE ONLY POPULATION AVERAGE SIGNALS. YET REGULATORY NETWORKS AND PERTURBATIONS ARE HETEROGENEOUS BETWEEN CELL CLASSES AND TYPES. SINGLE-CELL TECHNOLOGIES CAN OVERCOME THE CHALLENGE OF CELLULAR HETEROGENEITY AND PROVIDE DEEPER INSIGHT INTO CELL TYPE-SPECIFIC GENE REGULATORY PROGRAMS IN HEALTHY, DISEASED, AND CANCEROUS TISSUES. IN PRIOR WORK, WE DEVELOPED A SINGLE-CELL JOINT ASSAY OF HISTONE MODIFICATION AND RNA EXPRESSION (PAIRED-TAG), ENABLING CELL-TYPE-STRATIFIED EPIGENETIC PROFILING FROM BULK SAMPLES. THIS TECHNOLOGY HAS ATTRACTED CUSTOMERS IN BOTH ACADEMIC AND NONPROFIT RESEARCH. IN THE PROPOSED STUDY, WE WILL DEVELOP AUTOMATED PROTOCOLS AND EFFECT LABORATORY INFORMATICS SYSTEMS TO ESTABLISH A PAIRED-TAG SERVICES LABORATORY, WE WILL REFINE OUR PROTOCOL TO IMPROVE EXPERIMENTAL THROUGHPUT AND REDUCE COST, AND WE WILL DEVELOP A PAIRED-TAG "TF" PROTOCOL FOR PROFILING TRANSCRIPTION FACTOR BINDING PROFILES. IF SUCCESSFUL, THE RESEARCH WOULD ENABLE NEXT- GENERATION MULTI-OMIC ANALYSIS OF TUMOR OR DISEASE SAMPLES AT COMPARABLE COST TO SINGLE-OMIC TECHNOLOGIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $825.1k | 6/27/24 | ||
| Not listed | $1.1m | 7/3/23 | ||
| Not listed | $1.1m | 7/3/23 |